Mark E. Flanagan

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 667 citations · Full text

Immunology, Cell Death, Immunotherapy +21

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 331 citations · Full text

Immunology, Janus Tyrosine Kinases, Immunotherapy +19

Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson et al. · Journal of Medicinal Chemistry · 2014 · 318 citations

Combinatorial Chemistry, Drug Target, Thiol-reactive Covalent Inhibitors +17

Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach et al. · Journal of Medicinal Chemistry · 2018 · 160 citations · Full text

Immunodeficiencies, Janus Kinases, Immunology +22

DNA-encoded chemical libraries

Alexander L. Satz, Andreas Brunschweiger, Mark E. Flanagan et al. · Nature Reviews Methods Primers · 2022 · 157 citations

Nucleic Acid Chemistry, Bioorganic Chemistry, Natural Sciences +5